EPO clarifies reasons for CRISPR patent ruling

The European Patent Office (EPO) has now clarified its reasoning behind the decision to find against the Broad Institute of Massachusetts Institute of Technology (MIT) in the latest round of a major patent dispute concerning rights to commercialise the revolutionary gene editing technology CRISPR.

Read Complete Article

MITLA is a member of the INPLP

    Subscribe for the latest
    IT Law updates

    Receive the latest IT Law updates straight to your inbox, gain access to our exclusive industry events, keep up to date with MITLA.